Trabectedin
(Synonyms: 曲贝替定; Ecteinascidin 743; ET-743) 目录号 : GC18044
Trabectedin是一种具有强效抗肿瘤活性的四氢异喹啉生物碱。Trabectedin可选择性抑制与DNA损伤修复相关的转录因子,并阻断DNA核苷酸切除修复通路,导致DNA双链断裂和肿瘤细胞凋亡。Trabectedin还能调节肿瘤微环境,通过抑制肿瘤相关巨噬细胞的活性间接发挥抗肿瘤作用。Trabectedin常用于软组织肉瘤和卵巢癌的研究。
Cas No.:114899-77-3
Sample solution is provided at 25 µL, 10mM.
Trabectedin is a tetrahydroisoquinoline alkaloid with potent antitumor activity. Trabectedin can selectively inhibit transcription factors associated with DNA damage repair and block the DNA nucleotide excision repair pathway, leading to DNA double-strand breaks and tumor cell apoptosis. Trabectedin can also regulate the tumor microenvironment and indirectly exert antitumor effects by inhibiting the activity of tumor-associated macrophages. Trabectedin is often used in the study of soft tissue sarcoma and ovarian cancer [1-6].
Fifteen breast cancer samples were exposed to increasing concentrations of Trabectedin for 14 days, with dose-dependent tumor growth inhibition rates reaching 40%, 79%, and 100% at concentrations of 10nM, 100nM, and 1µM, respectively [5]. Prolonged exposure to Trabectedin induced a cytotoxic effect in 402.91 and 1765 cell lines, after 48 hours of continuous exposure to 2.5nM, cell death was 70% and 50%, respectively [6]. JN-DSRCT-1 cells are highly sensitive to increasing concentrations of Trabectedin (2.5nM, 24h), which induce a dose-dependent and transient G2/M cell cycle arrest [7].
In nude mouse models of MN/MCA1 fibrosarcoma, ID8 ovarian cancer, Lewis lung cancer, and MCA-fibrosarcoma, Trabectedin (0.15mg/kg, ip, 21d) modulates the tumor microenvironment by selectively targeting mononuclear phagocytes, especially tumor-associated macrophages (TAMs) and immunosuppressive myeloid suppressor cells (MDSCs), thereby exerting its antitumor efficacy [8]. In 4T1 cell and EMT6 TNBC models in BALB/c mice, Trabectedin (0.15mg/kg, ip, 15d) significantly slowed the growth of 4T1 and EMT6 tumors [9]. Treatment of C57BL/6J mice with Trabectedin (0.15mg/kg, ip, 42d) significantly reduced trabecular BV/TV and cortical BMD, while reducing serum P1NP as well as MS/BS and BFR/BS in mice, and inhibited mineralization and Runx2 gene expression in osteoblast culture [10].
References:
[1]. Takahashi N, Li W, Banerjee D, et al. Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo[J]. Cancer Research. 2002 Dec 1; 62(23): 6909-6915.
[2]. Atmaca H, Bozkurt E, Uzunoglu S, et al. A diverse induction of apoptosis by trabectedin in MCF-7 (HER2-/ER+) and MDA-MB-453 (HER2+/ER-) breast cancer cells[J]. Toxicology Letters. 2013 Aug 14; 221(2): 128-136
[3]. Cuevas C, Francesch A. Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem[J]. Natural Product Reports. 2009 Mar; 26(3): 322-337.
[4]. Carter NJ, Keam SJ. Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer[J]. Drugs. 2007; 67(15): 2257-2276.
[5] D'Incalci M, Zambelli A. Trabectedin for the treatment of breast cancer[J]. Expert Opinion on Investigational Drugs. 2016; 25(1): 105-115
[6]. Germano G, Frapolli R, Simone M, et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells[J]. Cancer Research. 2010 Mar 15; 70(6):2235-2244.
[7]. Uboldi S, Craparotta I, Colella G, et al. Mechanism of action of trabectedin in desmoplastic small round cell tumor cells[J]. BMC Cancer. 2017 Feb 6; 17(1): 107.
[8]. Germano G, Frapolli R, Belgiovine C, et al. Role of macrophage targeting in the antitumor activity of trabectedin[J]. Cancer Cell. 2013 Feb 11; 23(2): 249-262.
[9]. Schwarz E, Savardekar H, Zelinskas S, et al. Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer[J]. Cancer Immunology Research. 2025 Apr 2; 13(4): 560-576.
[10]. Sinder BP, Zweifler L, Koh AJ, et al. Bone Mass Is Compromised by the Chemotherapeutic Trabectedin in Association With Effects on Osteoblasts and Macrophage Efferocytosis[J]. Journal of Bone and Mineral Research. 2017 Oct; 32(10): 2116-2127.
Trabectedin是一种具有强效抗肿瘤活性的四氢异喹啉生物碱。Trabectedin可选择性抑制与DNA损伤修复相关的转录因子,并阻断DNA核苷酸切除修复通路,导致DNA双链断裂和肿瘤细胞凋亡。Trabectedin还能调节肿瘤微环境,通过抑制肿瘤相关巨噬细胞的活性间接发挥抗肿瘤作用。Trabectedin常用于软组织肉瘤和卵巢癌的研究 [1-6]。
15个乳腺癌样本暴露于浓度不断增加的Trabectedin(14d),剂量依赖性肿瘤生长抑制率分别在10nM、100nM和1µM浓度下达到40%、79%和100% [5]。长期暴露于Trabectedin的402.91和1765细胞系中会产生细胞毒性作用,在2.5nM浓度下持续暴露48h后,细胞死亡率分别为70%和50% [6]。JN-DSRCT-1细胞对浓度增加的Trabectedin(2.5nM,24h)高度敏感,这会诱导剂量依赖性和短暂性的G2/M细胞周期停滞 [7]。
在MN/MCA1纤维肉瘤、ID8卵巢癌、Lewis肺癌、MCA-纤维肉瘤裸鼠模型中,Trabectedin(0.15mg/kg,ip,21d)通过选择性靶向单核吞噬细胞,特别是肿瘤相关巨噬细胞(TAM)和免疫抑制性髓系抑制细胞(MDSC),调节肿瘤微环境,从而发挥其抗肿瘤功效 [8]。在BALB/c小鼠的4T1细胞和EMT6的TNBC模型中,Trabectedin(0.15mg/kg,ip,15d)显著减缓了4T1和EMT6肿瘤的生长 [9]。长期给予C57BL/6J小鼠Trabectedin(0.15mg/kg,ip,42d)可显著降低小梁BV/TV和皮质BMD,同时降低小鼠血清P1NP以及MS/BS和BFR/BS,并抑制成骨细胞培养中的矿化和Runx2基因表达 [10]。
Cell experiment [1]: | |
Cell lines | MLS cell lines, 402.91 and 1765 |
Preparation Method | MLS cell lines were cultured in RPMI 1640 containing 10% FCS, 1200mM Ultraglutamine, and Pen/Strep for 24h and then treated with different concentrations of Trabectedin for 1h, or as specified. |
Reaction Conditions | 0.5, 1, 1.5, 2, 2.5, 5, and 10nM; 1, 24, 48, and 72h |
Applications | Trabectedin exhibited a strong, dose-dependent effect on MLS cells lines, achieving a 50% growth reduction at 1.5nM. Treatment induced cell cycle arrest and a dose-dependent accumulation of cells in the S phase (5 and 10nM), followed by marked growth inhibition associated with G2/M phase arrest. |
Animal experiment [2]: | |
Animal models | MN/MCA1 fibrosarcoma, ID8 ovarian carcinoma, Lewis lung carcinoma, and MCA-fibrosarcoma |
Preparation Method | Three transplantable tumor models were used—MN/MCA1 fibrosarcoma, ID8 ovarian carcinoma, and Lewis lung carcinoma—along with a primary fibrosarcoma model induced by methylcholanthrene injection (MCA-fibrosarcoma). Trabectedin was administered once weekly for three cycles, followed by blood collection and leukocyte analysis by flow cytometry. |
Dosage form | 0.15mg/kg; ip; 21d |
Applications | Treatment with Trabectedin caused a rapid decrease (24–48h) in the number of blood monocytes (CD45+ CD11b+ CD115+ [macrophage colony-stimulating factor receptor]), while neutrophils (CD45+ CD11b+ CD115neg SSChigh), CD3 T cells, and CD19 B lymphocytes were unaffected. |
References: |
Cas No. | 114899-77-3 | SDF | |
别名 | 曲贝替定; Ecteinascidin 743; ET-743 | ||
Canonical SMILES | CC1=C(OC)C(O)=C2C3[C@@H]4[C@@H]5C6=C(C7=C(OCO7)C(C)=C6OC(C)=O)[C@@H](COC(C8(C9=CC(OC)=C(O)C=C9CCN8)CS5)=O)N4C(O)C(CC2=C1)N3C | ||
分子式 | C39H43N3O11S | 分子量 | 761.84 |
溶解度 | DMSO : 33.33 mg/mL (43.75 mM; Need ultrasonic) | 储存条件 | -20°C, protect from light, stored under nitrogen,unstable in solution, ready to use. |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 1.3126 mL | 6.5631 mL | 13.1261 mL |
5 mM | 0.2625 mL | 1.3126 mL | 2.6252 mL |
10 mM | 0.1313 mL | 0.6563 mL | 1.3126 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet